Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 May 9;7(9):1926-1928.
doi: 10.1182/bloodadvances.2022009177.

Curing CLL: one clone at a time

Burcu Aslan  1 , Shady I Tantawy  1 , Varsha Gandhi  1   2
Affiliations
Editorial

Curing CLL: one clone at a time

Burcu Aslan et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: V.G. has sponsored research agreements from Pharmacyclics, AbbVie, Acerta, Sunesis, and Loxo Oncology. The remaining authors declare no competing financial interests.

Figures

None
Outcomes of and challenges in therapy with covalent and noncovalent BTKi for CLL. Patients with CLL at diagnosis are expected to have BTKWT disease. When it is treated with covalent BTKi, 3 different outcomes [1], [2], and [3] are observed. [1] The majority of patients have a clinical response, their BTKWT status is presumed to be maintained, and they continue to receive covalent BTKi until discontinuation or disease progression (DP). [2] About 15-20% of patients are intolerant to covalent BTKi and discontinue therapy. Their BTKWT status is maintained, but they need treatment with other agents. When given noncovalent BTKi, they either respond to noncovalent BTKi and continue therapy or develop new non-C481 BTK mutations or presumably non-BTK mutations and need new therapeutics. [3] About 10-15% of patients have DP owing to BCR pathway mutation, with replacement of the cysteine residue in C481 (such as C481S and C481R) being the most prevalent substitution. When given noncovalent BTKi, they have responses and even sometimes experience resolution of the initial C481 (C481S) mutant clone. However, some of these patients have DP owing to development of a second-site (non-C481) mutant clone and clonal expansion. These new clones do not respond to treatment with covalent or noncovalent BTKi, and novel approaches are required for them. Rx, therapy; cBTKi, covalent BTK inhibitor; ncBTKi, noncovalent BTK inhibitor; WT, wild-type; mt, mutant.
See this image and copyright information in PMC

Comment on

References

    1. Naeem A, Utro F, Wang Q, et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023;7(9):1929–1943. - PMC - PubMed
    1. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223. - PMC - PubMed
    1. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. - PMC - PubMed
    1. Estupiñán H, Wang Q, Berglöf A, et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia. 2021;35(5):1317–1329. - PMC - PubMed
    1. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901. - PMC - PubMed

MeSH terms